688016 Shanghai MicroPort Endovascular MedTech(Group)Co.,Ltd.
- 193.47
- -1.09-0.56%
Shanghai MicroPort Endovascular MedTech(Group)Co.,Ltd. News
Heart Heart Medical (688016.SH) 2023 equity distribution: 3 yuan per share, free 0.49 shares, shares registered on May 13
Heart Heart Healthcare (688016.SH) issued the 2023 equity distribution implementation notice. This time, profits will be distributed to Israel...
Heart Care (688016): First-quarter profits exceeded expectations, and cost control accelerated markedly
1Q24 net profit exceeded our expectations. The company announced 1Q24 results: revenue of 358 million yuan, +25% year over year; net profit attributed/deducted from mother was 1.84 billion yuan/178 million yuan, respectively, +48%/49% year over year. revenues
Heart Care (688016): Profit side growth exceeds expectations and is optimistic about the release of innovative products
Event: The company released its report for the first quarter of 2024, and achieved operating income of 358 million yuan (+25.38%) and net profit to mother of 184 million yuan (+47.62%) in the first quarter of 2024.
Heart Care (688016): Revenue growth is in line with expectations, and profit margins have increased due to multiple factors
Matters: The company released its 2024 quarterly report. Q1 achieved revenue of 358 million yuan (+25.38%), realized net profit to mother of 184 million yuan (+47.62%), and net profit after deducting non-return to mother of 178 million yuan (+48.
Cardiac Healthcare (688016.SH) announced first-quarter results, net profit of 184 million yuan, up 47.62% year-on-year
Heart Heart Healthcare (688016.SH) disclosed its report for the first quarter of 2024. The company achieved operating revenue during the reporting period...
Heart Care (688016): Performance is in line with expectations, overseas revenue continues to grow rapidly
Core idea In 2023, the market coverage of the company's three core products, Castor, Minos, and Peripheral Medicine, continued to increase, and the number of innovative products Talos and Fontus admissions and terminal implants increased rapidly
Caixin Securities released a research report on April 9 stating that it gave Cardiac Healthcare (688016.SH) a purchase rating. The main reasons for the rating include: 1) achieving steady growth in aortic stents and rapid release of intraoperative stents
Caixin Securities released a research report on April 9 stating that it gave Cardiac Healthcare (688016.SH) a purchase rating. The main reasons for the rating include: 1) achieving steady growth in aortic stents and rapid release of intraoperative stents and peripheral products; 2) increasing investment in innovative research and development to actively promote the launch of various products; 3) accelerating global development and increasing overseas market coverage. (Mainichi Keizai Shimbun)
Cardiac Medicine (688016): Aortic Interventions Leading Peripheral Interventions, Rising Performance Growth
Incident: On March 27, 2024, Cardiac Medical released its 2023 annual report. The company achieved revenue of 1,187 billion yuan (+32.43%), net profit to mother of 492 million yuan (+37.98%), deducting net profit from non-return to mother
Cardiac Healthcare (688016): 2023 performance is in line with expectations, R&D is progressing smoothly
The 2023 results are in line with expectations: the company released its 2023 annual report. During the reporting period, it achieved operating income of 1,187 million yuan, an increase of 32% over the previous year; realized net profit to mother of 492 million yuan, an increase of 38% over the previous year; achieved deduction of negative funds
Cardiac Healthcare (688016): Steady performance, peripheral products are expected to continue to be approved
The 2023 results are in line with our expectations. The company announced 2023 results: revenue of 1.19 billion yuan, +32% year over year; net profit to mother of 490 million yuan, +38% year over year. The results were in line with our expectations. Various development trends
Heart Care (688016): Performance growth slightly exceeds expectations, domestic in-depth channels+overseas markets continue to develop innovative products and accelerate the release of innovative products
Incident: The company released its 2023 annual report, achieving full year operating income of 1,187 million yuan (YoY +32.43%), net profit to mother of 492 million yuan (YoY +37.98%), deducting net profit of non-return to mother4
Cardiac Healthcare (688016): Performance achieved rapid growth and progressed steadily in the research pipeline
Event: The company released its 2023 annual report. The company achieved operating income of 1,187 million yuan (+32.43%) and net profit to mother of 492 million yuan (+37.98%) for the full year of 2023.
Cardiac Healthcare (688016): Resilience in performance highlights outstanding overseas performance
Guide to this report: Driven by new products, the company's various product lines are growing rapidly, advancing in the research pipeline, providing lasting growth momentum, and maintaining an increase in holdings rating. Key investment points: Maintain an increase in holdings rating. Maintain the 2024-2025 EPS forecast
Heart Care (688016): High growth in 2023 to achieve product penetration and iterative guarantee growth sustainability
Matters: The company released its 2023 annual report and achieved full-year revenue of 1,187 million yuan (+32.43%), realized net profit of 492 million yuan (+37.98%), and net profit after deduction of 462 million yuan (+42)
Minimally Invasive Healthcare (00853): Cardiac Medical Technology's net profit to the mother in 2023 was 492 million yuan, up 37.98% year-on-year
Minimally Invasive Healthcare (00853) released Affiliated Cardiac Medical Technology, which has been reviewed for 12 months ending December 31, 2023...
Express News | Heart Care: Net profit increased 37.98% year-on-year in 2023, plans to give 10 free 4.9 shares and distribute 30 yuan
Heart Care (688016) Company Review: New Product Admission Promotion Rapid R&D Pipeline Advances Smoothly
On March 27, 2024, the company released its 2023 annual report. In 2023, the company achieved revenue of 1,187 billion yuan, +32% year-on-year; net profit to mother of 492 million yuan, +38% year-on-year; realized deductions
Cardiovascular Medicine (688016): Leading aortic intervention performance continues to increase
Incident: The company released its 2023 annual report. In 2023, it achieved operating income of 1.19 billion yuan (+32.4%), net profit to mother of 490 million yuan (+38%), and net profit of non-return to mother of 450 million yuan (+42.7%)
Cardiovascular Medicine (688016): Aortic intervention leading peripheral products have entered a concentrated harvest period
Investment points: Aortic dissection is at high risk, and the number of interventional procedures continues to increase: Aortic diseases mainly include aortic dissection and aortic aneurysm. Aortic dissection is a fatal disease, and the case fatality rate within 6 hours of untreated acute dissection will exceed 22.
Express News | Eight Shanghai enterprises were approved as national enterprise technology centers in 2023
Analysis
Price Target
No Data
